Journal article
Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL
- Abstract:
-
Objectives To assess 52-week safety and efficacy of bimekizumab in patients with active psoriatic arthritis (PsA) and prior inadequate response/intolerance to tumour necrosis factor inhibitors.
Methods Patients completing the 16-week phase III double-blind, placebo-controlled BE COMPLETE (NCT03896581) study entered the open-label extension, BE VITAL (NCT04009499). All patients in BE VITAL received 160 mg bimekizumab every 4 weeks. Safety and effica...
Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Version of record, pdf, 2.6MB, Terms of use)
-
- Publisher copy:
- 10.1136/rmdopen-2023-003855
Authors
Bibliographic Details
- Publisher:
- BMJ Publishing Group
- Journal:
- RMD Open More from this journal
- Volume:
- 10
- Issue:
- 1
- Article number:
- e003855
- Publication date:
- 2024-02-22
- Acceptance date:
- 2024-01-10
- DOI:
- EISSN:
-
2056-5933
Item Description
- Language:
-
English
- Pubs id:
-
1598621
- Local pid:
-
pubs:1598621
- Deposit date:
-
2024-01-12
Terms of use
- Copyright holder:
- Coates et al.
- Copyright date:
- 2024
- Rights statement:
- © Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial.
Metrics
If you are the owner of this record, you can report an update to it here: Report update to this record